Department of Therapeutics and Pharmacology, The Queen's University, Belfast, Northern Ireland.
Br J Clin Pharmacol. 1974 Feb;1(1):27-35. doi: 10.1111/j.1365-2125.1974.tb00202.x.
1 Kö 1313 competitively inhibited the increases in heart rate produced by isoprenaline in anaesthetized dogs. 2 Kö 1313 was 35 times more active than propranolol in blocking an isoprenaline induced tachycardia in anaesthetized dogs but only three times more active in blocking the increase in femoral blood flow produced by the injection of isoprenaline into the femoral artery. These observations suggest that Kö 1313 may have some cardio-selective activity. 3 When a series of doses of Kö 1313 was injected intravenously into anaesthetized dogs, the lower doses decreased heart rate while the larger doses increased heart rate. The same doses of propranolol reduced heart rate. 4 In lightly anaesthetized dogs, a series of doses of Kö 1313 progressively increased heart rate while propranolol produced little change. These observations indicate that Kö 1313 has slight intrinsic sympathomimetic activity. 5 The oral administration of Kö 1313 and propranolol had no effect on resting heart rate in man but reduced the increases produced by head-up tilt, standing and exercise.
Kö 1313 竞争性地抑制了麻醉犬异丙肾上腺素引起的心率增加。
Kö 1313 在阻断麻醉犬异丙肾上腺素引起的心动过速方面比普萘洛尔活性高 35 倍,但在阻断异丙肾上腺素注入股动脉引起的股血流增加方面仅高 3 倍。这些观察结果表明,Kö 1313 可能具有一定的心脏选择性活性。
当一系列剂量的 Kö 1313 静脉注射到麻醉犬中时,较低剂量降低心率,而较大剂量增加心率。相同剂量的普萘洛尔降低心率。
在轻度麻醉的狗中,一系列剂量的 Kö 1313 逐渐增加心率,而普萘洛尔几乎没有变化。这些观察结果表明,Kö 1313 具有轻微的内在拟交感神经活性。
Kö 1313 和普萘洛尔的口服给药对静息心率在人没有影响,但减少了头高位倾斜、站立和运动引起的心率增加。